Scholarlink

Background <p>Colorectal cancer (CRC) represents a growing global health burden, particularly in developing countries. Mesenchymal stem cells (MSCs) have been reported to suppress tumor progression partly through the release of exosomes that deliver therapeutic molecules. However, the therapeutic potential of engineered MSC-derived exosomal microRNAs (Exo-miRNAs) in CRC remains largely unexplored.</p> Methods <p>Plasma exosome miRNA sequencing was performed to identify dysregulated miRNAs in CRC. Gain- and loss-of-function assays were conducted to evaluate the biological effects of candidate miRNAs in CRC cells. Human mesenchymal stem cells (hMSCs) were engineered to overexpress miR-3614-5p via Lipofectamine-mediated transfection, and exosomes enriched with miR-3614-5p were isolated and characterized. The effects of engineered hMSC-derived exosomal miR-3614-5p (Exo-miR-3614-5p) on CRC progression were assessed both in vitro and in vivo. Mechanistic studies were performed to identify downstream targets and signaling pathways.</p> Results <p>miR-3614-5p was identified as a therapeutic miRNA that was significantly downregulated in CRC. Engineered hMSCs efficiently loaded miR-3614-5p into secreted exosomes. Treatment with Exo-miR-3614-5p markedly suppressed CRC cell proliferation in vitro and inhibited tumor growth in vivo. Mechanistically, miR-3614-5p directly bound to the 3′ untranslated region (3′UTR) of IL7Rα, resulting in translational repression and subsequent inactivation of the JAK2/STAT3 signaling pathway. In addition, miR-3614-5p exhibited potential diagnostic value for CRC.</p> Conclusions <p>This study demonstrates that engineered hMSC-derived exosomal miR-3614-5p effectively inhibits CRC progression primarily through downregulation of IL7Rα and suppression of the JAK2/STAT3 signaling pathway. These findings suggest that Exo-miR-3614-5p represents a promising therapeutic and diagnostic candidate for CRC.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Human mesenchymal stem cell-derived miR-3614-5p exosomes suppress progression of colorectal cancer by targeting IL7Rα

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月21日

查看全文
  • Mengling Ye,
  • Yingzhen Bian,
  • Yanyan Lin,
  • Shirong Li,
  • Lixia Jiang,
  • Jinlu Wu,
  • Yuxuan Xie,
  • Shufang Ning,
  • Yuyang Liu,
  • Jinglei Huang,
  • Xinxing Lei,
  • Litu Zhang

摘要

Background

Colorectal cancer (CRC) represents a growing global health burden, particularly in developing countries. Mesenchymal stem cells (MSCs) have been reported to suppress tumor progression partly through the release of exosomes that deliver therapeutic molecules. However, the therapeutic potential of engineered MSC-derived exosomal microRNAs (Exo-miRNAs) in CRC remains largely unexplored.

Methods

Plasma exosome miRNA sequencing was performed to identify dysregulated miRNAs in CRC. Gain- and loss-of-function assays were conducted to evaluate the biological effects of candidate miRNAs in CRC cells. Human mesenchymal stem cells (hMSCs) were engineered to overexpress miR-3614-5p via Lipofectamine-mediated transfection, and exosomes enriched with miR-3614-5p were isolated and characterized. The effects of engineered hMSC-derived exosomal miR-3614-5p (Exo-miR-3614-5p) on CRC progression were assessed both in vitro and in vivo. Mechanistic studies were performed to identify downstream targets and signaling pathways.

Results

miR-3614-5p was identified as a therapeutic miRNA that was significantly downregulated in CRC. Engineered hMSCs efficiently loaded miR-3614-5p into secreted exosomes. Treatment with Exo-miR-3614-5p markedly suppressed CRC cell proliferation in vitro and inhibited tumor growth in vivo. Mechanistically, miR-3614-5p directly bound to the 3′ untranslated region (3′UTR) of IL7Rα, resulting in translational repression and subsequent inactivation of the JAK2/STAT3 signaling pathway. In addition, miR-3614-5p exhibited potential diagnostic value for CRC.

Conclusions

This study demonstrates that engineered hMSC-derived exosomal miR-3614-5p effectively inhibits CRC progression primarily through downregulation of IL7Rα and suppression of the JAK2/STAT3 signaling pathway. These findings suggest that Exo-miR-3614-5p represents a promising therapeutic and diagnostic candidate for CRC.

Graphical Abstract